Zedoresertib
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Glioblastoma · Phase 1/2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
WIN-B NCT06612203 · Advanced Breast Cancer Registry: NCT06612203 | 1/2 | Phase Ib - Debio 0123's recommended phase II dose (RP2D) when administered in combination with Sacituzumab govitecan in patients with TNBC or HR+/HER2- metastatic breast cancer. (Baseline up to 42 days.); Phase II - Efficacy in terms of objective response rate (ORR) as per RECIST v.1.1 in each cohort. (Approximately 9 months from baseline.) 2027-02 | In progress: results expected 1 Feb 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other WEE1 kinase drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Glioblastoma: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zedoresertib: this drug | Phase 1/2 | Small molecule | WEE1 kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Phase 3 | Small molecule | PARP1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Temferon | Phase 1/2 | Gene therapy / editing | Interferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cells | not yet graded | No reviewed efficacy summary in this indication | |
| TNG456 | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD1390 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986463 | Phase 1(overall) | Small molecule | WEE1 kinase | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Adavosertib | Discontinued | Small molecule | WEE1 kinase | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Ralometostat | Discontinued | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zedoresertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.